BNP Paribas Financial Markets Raises Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

BNP Paribas Financial Markets boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 59.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,466 shares of the company's stock after acquiring an additional 35,284 shares during the quarter. BNP Paribas Financial Markets owned 0.20% of Amphastar Pharmaceuticals worth $4,584,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. TD Asset Management Inc boosted its holdings in Amphastar Pharmaceuticals by 67.4% during the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company's stock valued at $67,663,000 after acquiring an additional 680,976 shares during the period. Epoch Investment Partners Inc. boosted its holdings in Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company's stock valued at $43,154,000 after acquiring an additional 280,390 shares during the period. American Century Companies Inc. boosted its holdings in Amphastar Pharmaceuticals by 19.7% during the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company's stock valued at $29,616,000 after acquiring an additional 121,764 shares during the period. Millennium Management LLC boosted its holdings in Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company's stock valued at $29,550,000 after acquiring an additional 338,653 shares during the period. Finally, Boston Trust Walden Corp purchased a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at about $26,189,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Down 1.0 %

Shares of Amphastar Pharmaceuticals stock traded down $0.46 on Wednesday, reaching $44.46. 146,581 shares of the company were exchanged, compared to its average volume of 397,348. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92. The company has a market cap of $2.14 billion, a P/E ratio of 14.97, a price-to-earnings-growth ratio of 0.91 and a beta of 0.78. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock's 50 day moving average price is $47.73 and its 200-day moving average price is $44.60.

Insider Buying and Selling

In related news, Director Richard K. Prins sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the sale, the director now owns 31,471 shares in the company, valued at $1,535,784.80. The trade was a 13.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Peters sold 7,426 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the sale, the chief financial officer now owns 94,103 shares of the company's stock, valued at approximately $4,898,061.15. The trade was a 7.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,533 shares of company stock worth $1,378,252 over the last 90 days. 27.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on AMPH shares. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating for the company in a report on Thursday, August 8th. StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price objective for the company. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $60.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.